Long-Term Efficacy of Pegylated Interferon Alpha-2b in Behçet’s Uveitis: A Small Case Series

References

• Behçet H. Über rezidivierende aphthöse durch ein virus verursachte Geschwüre am Mund, am Auge, und an den Genitalien. Dermatol Wochenschr. 1937;105:1152–1157.
   Google Scholar
• Isaacs A, Lindenmann J. Virus interference. I Interferon Proc R Soc Lond B Biol Sci. 1957 Sep 12;147(927):258–267.
   PubMed Web of Science ®Google Scholar
• Tsambaos D, Eichelberg D, Goos M. Behçet’s syndrome: Treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res. 1986;278(4):335–336.
   PubMed Web of Science ®Google Scholar
• Kotter I, Gunaydin I, Zierhut M, et al. The use of interferon alpha in Behçet Disease: Review of the literature. Semin Arthritis Rheum. 2004;33(5):320–335.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon alfa therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol. 2006;244(12):1692–1695.
   PubMed Web of Science ®Google Scholar
• Onal S, Kazokoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. Arch Ophthalmol. 2011;129(3):288–294.
   PubMed Web of Science ®Google Scholar
• Yalçindağ FN, Uzun A. Results of interferon alpha-2a therapy in patients with Behcet’s disease. J Ocul Pharmacol Ther. 2012;28(4):439–443.
   PubMed Web of Science ®Google Scholar
• Plskova J, Greiner K, Forrester JV. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol. 2007;144(1):55–61.
   PubMed Web of Science ®Google Scholar
• Burgueño-Montañés C, Pérez-Álvarez R. Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C. Arch Soc Esp Oftalmol. 2011;86(6):193–195.
   PubMedGoogle Scholar
• Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease. Lanset. 1990;335(8697):1078–1080.
   Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509–516.
   PubMed Web of Science ®Google Scholar
• Diwo E, Gueudry J, Saadoun D, et al. Long-term efficacy of interferon in severe uveitis associated with behçet disease. Ocul Immunol Inflamm. 2016;19:1–9.
   Google Scholar
• Caliceti P. Pharmacokinetics of pegylated interferons: What is misleading? Dig Liver Dis. 2004;36(Suppl 3):334–339.
   Google Scholar
• Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet. 1990;19(5):390–399.
   PubMed Web of Science ®Google Scholar
• Abuchowski A, Van Es T, Palczuk NC, et al. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem. 1977;252(11):3578–3581.
   PubMed Web of Science ®Google Scholar
• Gaertner HF, Offord RE. Site-specific attachment of functionalized poly (ethylene glycol) to the amino terminus of proteins. Bioconjug Chem. 1996;7(1):38–44.
   PubMed Web of Science ®Google Scholar
• Kozlowski A, Harris JM. Improvements in protein PEGylation: Pegylated interferons for treatment of hepatitis C. J Control Release. 2001;72(1–3):217–224.
   PubMed Web of Science ®Google Scholar
• Lightman S, Taylor SR, Bunce C, et al. Pegylated interferon-α-2b reduces corticosteroid requirement in patients with Behçet’s disease with upregulation of circulating regulatory T cells and reduction of Th17. Ann Rheum Dis. 2015;74(6):1138–1144.
   PubMed Web of Science ®Google Scholar
• Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: Published evidence and prospective trial data. Ann Rheum Dis. 2006;65(3):285–293.
   PubMed Web of Science ®Google Scholar
• Bielefeld P, Devilliers H, Deschasse C, et al. Potential of pegylated interferon alpha-2a in Behçet uveitis: A report of five cases. Ocul Immunol Inflamm. 2016;24(5):599–602.
   PubMed Web of Science ®Google Scholar
• Tokai R, Ikeda T, Miyaura T, et al. Interferon-associated retinopathy and cystoid macular edema. Arch Ophthalmol. 2001;119(7):1077–1079.
   PubMedGoogle Scholar
• Sene D, Touitou V, Bodaghi B, et al. Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C. World J Gastroenterol. 2007;13(22):3137–3140.
   PubMed Web of Science ®Google Scholar
• Kang HY, Shin MC. Pegylated interferon-associated severe retinopathy in a patient with chronic hepatitis. Korean J Ophthalmol. 2012;26(2):147–150.
   PubMedGoogle Scholar
• Sheth HG, Michaelides M, Siriwardena D. Cystoid macular edema and visual loss as sequelae to interferon alpha treatment of systemic hepatitis C. Indian J Ophthalmol. 2010;58(2):147–148.
   PubMed Web of Science ®Google Scholar
• Narkewicz MR, Rosenthal P, Schwarz KB, et al. PEDS-C Study Group. Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferon. J Pediatr Gastroenterol Nutr. 2010;51(2):183–186.
   PubMed Web of Science ®Google Scholar
• Benitah NR, Sobrin L, Papaliodis GN. The use of biologic agents in the treatment of ocular manifestations of Behcet’s disease. Semin Ophthalmol. 2011;26(4–5):295–303.
   PubMed Web of Science ®Google Scholar
• Perry CM, Jarvis B. Spotlight on peginterferon-alpha-2a (40KD) in chronic hepatitis C. Bio Drugs. 2002;16(3):213–217.
   Google Scholar
• Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003;124(6):1711–1719.
   PubMed Web of Science ®Google Scholar
• Malik NN, Sheth HG, Ackerman N, et al. A prospective study of change in visual function in patients treated with pegylated interferon alpha for hepatitis C in the UK. Br J Ophthalmol. 2008;92(2):256–258.
   PubMed Web of Science ®Google Scholar